Patents by Inventor John Richard Langridge

John Richard Langridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8865778
    Abstract: A controlled release excipient composition suitable in formulation of a slow or extended release tablet, contains a synergistic mixture of substantially uncross-linked carboxymethyl starch, or sodium starch glycolate (SSG), and a hydrophilic, non-ionic cellulose ether, preferably hydroxypropylmethylcellulose. Whether or not a SSG in the mixture is sufficiently uncross-linked in the context of the invention can be determined by sedimentation: 0.25 g of the formulation in 100 ml deionized water after 24 hours at 25° C., if subjected to centrifugation at 6080 G at 25° C. for 15 minutes, should exhibit a sedimentation volume of more than 60 ml.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: October 21, 2014
    Assignee: Campina Nederland Holding B.V.
    Inventors: Linqiu Cao, John Richard Langridge, Alexander Wilhelmus Van Gessel
  • Publication number: 20100087549
    Abstract: A controlled release excipient composition suitable in formulation of a slow or extended release tablet, contains a synergistic mixture of substantially uncross-linked carboxymethyl starch, or sodium starch glycolate (SSG), and a hydrophilic, non-ionic cellulose ether, preferably hydroxypropylmethylcellulose. Whether or not a SSG in the mixture is sufficiently uncross-linked in the context of the invention can be determined by sedimentation: 0.25 g of the formulation in 100 ml deionized water after 24 hours at 25° C., if subjected to centrifugation at 6080 G at 25° C. for 15 minutes, should exhibit a sedimentation volume of more than 60 ml.
    Type: Application
    Filed: December 4, 2007
    Publication date: April 8, 2010
    Applicant: CAMPINA NEDERLAND HOLDING B.V.
    Inventors: Linqiu Cao, John Richard Langridge, Alexander Wilhelmus Van Gessel
  • Publication number: 20040097514
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: July 7, 2003
    Publication date: May 20, 2004
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Publication number: 20040029890
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/nL.
    Type: Application
    Filed: July 7, 2003
    Publication date: February 12, 2004
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Publication number: 20030100566
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: September 27, 2002
    Publication date: May 29, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Publication number: 20030099705
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: September 27, 2002
    Publication date: May 29, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Patent number: 6303607
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: May 27, 1999
    Date of Patent: October 16, 2001
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge